Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.
Inactivating mutations in either TSC1 or TSC2 cause Tuberous Sclerosis Complex, an autosomal dominant disorder, characterized by multi-system tumor and hamartoma development. Mutation and loss of function of TSC1 and/or TSC2 also occur in a variety of sporadic cancers, and rapamycin and related drug...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0248380 |
| _version_ | 1818002188336627712 |
|---|---|
| author | Evelyn M Mrozek Vineeta Bajaj Yanan Guo Izabela A Malinowska Jianming Zhang David J Kwiatkowski |
| author_facet | Evelyn M Mrozek Vineeta Bajaj Yanan Guo Izabela A Malinowska Jianming Zhang David J Kwiatkowski |
| author_sort | Evelyn M Mrozek |
| collection | DOAJ |
| description | Inactivating mutations in either TSC1 or TSC2 cause Tuberous Sclerosis Complex, an autosomal dominant disorder, characterized by multi-system tumor and hamartoma development. Mutation and loss of function of TSC1 and/or TSC2 also occur in a variety of sporadic cancers, and rapamycin and related drugs show highly variable treatment benefit in patients with such cancers. The TSC1 and TSC2 proteins function in a complex that inhibits mTORC1, a key regulator of cell growth, which acts to enhance anabolic biosynthetic pathways. In this study, we identified and validated five cancer cell lines with TSC1 or TSC2 mutations and performed a kinase inhibitor drug screen with 197 compounds. The five cell lines were sensitive to several mTOR inhibitors, and cell cycle kinase and HSP90 kinase inhibitors. The IC50 for Torin1 and INK128, both mTOR kinase inhibitors, was significantly increased in three TSC2 null cell lines in which TSC2 expression was restored. Rapamycin was significantly more effective than either INK128 or ganetespib (an HSP90 inhibitor) in reducing the growth of TSC2 null SNU-398 cells in a xenograft model. Combination ganetespib-rapamycin showed no significant enhancement of growth suppression over rapamycin. Hence, although HSP90 inhibitors show strong inhibition of TSC1/TSC2 null cell line growth in vitro, ganetespib showed little benefit at standard dosage in vivo. In contrast, rapamycin which showed very modest growth inhibition in vitro was the best agent for in vivo treatment, but did not cause tumor regression, only growth delay. |
| first_indexed | 2024-04-14T03:42:27Z |
| format | Article |
| id | doaj.art-909a6fb01eae496fab917357e7b74006 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-14T03:42:27Z |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-909a6fb01eae496fab917357e7b740062022-12-22T02:14:26ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01164e024838010.1371/journal.pone.0248380Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.Evelyn M MrozekVineeta BajajYanan GuoIzabela A MalinowskaJianming ZhangDavid J KwiatkowskiInactivating mutations in either TSC1 or TSC2 cause Tuberous Sclerosis Complex, an autosomal dominant disorder, characterized by multi-system tumor and hamartoma development. Mutation and loss of function of TSC1 and/or TSC2 also occur in a variety of sporadic cancers, and rapamycin and related drugs show highly variable treatment benefit in patients with such cancers. The TSC1 and TSC2 proteins function in a complex that inhibits mTORC1, a key regulator of cell growth, which acts to enhance anabolic biosynthetic pathways. In this study, we identified and validated five cancer cell lines with TSC1 or TSC2 mutations and performed a kinase inhibitor drug screen with 197 compounds. The five cell lines were sensitive to several mTOR inhibitors, and cell cycle kinase and HSP90 kinase inhibitors. The IC50 for Torin1 and INK128, both mTOR kinase inhibitors, was significantly increased in three TSC2 null cell lines in which TSC2 expression was restored. Rapamycin was significantly more effective than either INK128 or ganetespib (an HSP90 inhibitor) in reducing the growth of TSC2 null SNU-398 cells in a xenograft model. Combination ganetespib-rapamycin showed no significant enhancement of growth suppression over rapamycin. Hence, although HSP90 inhibitors show strong inhibition of TSC1/TSC2 null cell line growth in vitro, ganetespib showed little benefit at standard dosage in vivo. In contrast, rapamycin which showed very modest growth inhibition in vitro was the best agent for in vivo treatment, but did not cause tumor regression, only growth delay.https://doi.org/10.1371/journal.pone.0248380 |
| spellingShingle | Evelyn M Mrozek Vineeta Bajaj Yanan Guo Izabela A Malinowska Jianming Zhang David J Kwiatkowski Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer. PLoS ONE |
| title | Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer. |
| title_full | Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer. |
| title_fullStr | Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer. |
| title_full_unstemmed | Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer. |
| title_short | Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer. |
| title_sort | evaluation of hsp90 and mtor inhibitors as potential drugs for the treatment of tsc1 tsc2 deficient cancer |
| url | https://doi.org/10.1371/journal.pone.0248380 |
| work_keys_str_mv | AT evelynmmrozek evaluationofhsp90andmtorinhibitorsaspotentialdrugsforthetreatmentoftsc1tsc2deficientcancer AT vineetabajaj evaluationofhsp90andmtorinhibitorsaspotentialdrugsforthetreatmentoftsc1tsc2deficientcancer AT yananguo evaluationofhsp90andmtorinhibitorsaspotentialdrugsforthetreatmentoftsc1tsc2deficientcancer AT izabelaamalinowska evaluationofhsp90andmtorinhibitorsaspotentialdrugsforthetreatmentoftsc1tsc2deficientcancer AT jianmingzhang evaluationofhsp90andmtorinhibitorsaspotentialdrugsforthetreatmentoftsc1tsc2deficientcancer AT davidjkwiatkowski evaluationofhsp90andmtorinhibitorsaspotentialdrugsforthetreatmentoftsc1tsc2deficientcancer |